AR and cancer: [14] have developed a peptide PROTAC drug targeting p300, which can effectively degrade p300 and kill cancer cells in castration‐resistant prostate cancer (CRPC), androgen receptor (AR)‐negative, and neuroendocrine prostate cancer (NEPC) cells, greatly promoting the development of precision medicine.